Futura Medical plc

LSE FUM.L

Futura Medical plc Operating Cash Flow for the year ending December 31, 2023: USD 725.55 K

Futura Medical plc Operating Cash Flow is USD 725.55 K for the year ending December 31, 2023, a 110.39% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Futura Medical plc Operating Cash Flow for the year ending December 31, 2022 was USD -6.98 M, a -33.17% change year over year.
Futura Medical plc Operating Cash Flow for the year ending December 31, 2021 was USD -5.24 M, a 15.52% change year over year.
Futura Medical plc Operating Cash Flow for the year ending December 31, 2020 was USD -6.20 M, a 29.65% change year over year.
Futura Medical plc Operating Cash Flow for the year ending December 31, 2019 was USD -8.82 M, a -47.05% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

LSE: FUM.L

Futura Medical plc

CEO	Mr. James Henry Barder
IPO Date	July 22, 2003
Location	United Kingdom
Headquarters	Surrey Technology Centre
Employees	12
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies Eyewear Personal Care

Description

Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

Key trends

Past 5 years